## GRAL: GRAIL, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.5% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($83.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $110 | $85 | +29% |
| 2025-11-17 | Canaccord Genui | $105 | $85 | +24% |
| 2025-11-12 | Guggenheim | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-17 | Canaccord Genui | main | Buy |
| 2025-11-12 | Guggenheim | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 4 |

**Top Holders:**
- Blackrock Inc.: 6.3% (+0.7%)
- Primecap Management : 5.2% (-1.6%)
- CRCM LP: 4.7% (-49.5%)
- Vanguard Group Inc: 4.7% (-4.5%)
- Baker Bros. Advisors: 4.2% (0.0%)

### Key Risks

1. High beta (3.71) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-2.3% 5d) with bearish MACD, trend may be turning.
3. High short interest (15.9%, 4.7 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (7.6x), low leverage (D/E 0.16). Analyst sentiment positive (2 raises, avg +26%). Institutional flow bullish (4 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.9B |
| Beta | 1.00 |
| 52W Range | $16.10 - $115.76 |
| Short Interest | 15.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 5.8% to 3.5% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.5pp (needs >4.0% for momentum thesis). MRS_5 (-1.2%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 5.5% shows strong absolute momentum above own 20MA. Outperforming sector by 6.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.45% (CS: 78) | Neutral |
| RSI_14 | 56.2 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 1.055x | Above |
| vs SMA50 | 1.189x | Above |
| vs SMA200 | 2.073x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.80
- **Stop Loss:** $83.10 (16.7% risk)
- **Target:** $116.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $2,894.20
- **Portfolio %:** 2.89%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-19 (Est: $-2.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-3.27 | $-2.46 | +24.7% |
| 2025Q2 | $-3.56 | $-3.18 | +10.8% |
| 2025Q1 | $-3.80 | $-3.10 | +18.5% |
| 2024Q4 | $-4.97 | $-2.89 | +41.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*